Siemens current product support (cps) team investigated the issue.Investigation summary: ctni testpak lot 235151002 demonstrated acceptable performance when tested internally.When lot 235151002 was tested with bio-rad qc and cap samples, the lot performed as expected.This lot also had comparable performance to a second ctni testpak lot which was tested at the same time.Neither of the patient samples was returned, so the impact of the sample on the discrepant result could not be investigated.Based on the fact that there was a discrepancy between analyzers, a possible cause could have been antibody interference in the stratus cs assay that caused the stratus cs to provide an elevated result.
|